Previous close | 67.70 |
Open | 67.70 |
Bid | 67.70 x 1500 |
Ask | 67.75 x 8800 |
Day's range | 67.70 - 67.70 |
52-week range | 14.52 - 68.00 |
Volume | |
Avg. volume | 453,403 |
Market cap | 2.553B |
Beta (5Y monthly) | 0.60 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
PLANEGG/MUNICH, Germany, April 11, 2024--The Management Board and Supervisory Board of MorphoSys AG (FSE: MOR; NASDAQ: MOR) today issued a joint reasoned statement on the voluntary public takeover offer by Novartis BidCo AG, a wholly owned indirect subsidiary of Novartis AG (hereinafter collectively referred to as "Novartis"), recommending that shareholders accept the offer and tender their MorphoSys shares. Novartis offers MorphoSys shareholders € 68.00 per share in cash, representing a total e
PLANEGG/MUNICH, Germany, March 13, 2024--MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the fourth quarter and the full year 2023.
PLANEGG/MUNICH, Germany, December 11, 2023--MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced comprehensive results from the Phase 3 MANIFEST-2 study investigating pelabresib, an investigational BET inhibitor, in combination with the JAK inhibitor ruxolitinib in JAK inhibitor-naïve patients with myelofibrosis. These findings were presented in an oral presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, California.